Full Press Release Details
Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY)
("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived
therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate,
MEAI-based molecule CMND-100, for use in its first in-human clinical trial.
trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD).
our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial," said Dr. Adi Zuloff-Shani,
Clearmind's Chief Executive Officer. "Our pre-clinical positive results indicated the potential of our unique treatment for
AUD. We continue to execute the final steps necessary in order to commence our clinical program."
drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
Clearmind Medicine Inc.
is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to
solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Company's intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for
its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build
of Clearmind are listed for trading on Nasdaq under the symbol "CMND", the Canadian Securities Exchange under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol "CWY".
further information, please contact:
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking
statements. For example, the Company is using forward-looking statements when it discusses clinical batches production of its novel psychedelic-derived
drug candidate, the Company's upcoming FIH clinical trial, and any future correspondence with the FDA. Forward-looking statements
are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance
that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is
expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could
cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed
description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to
time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's
final prospectus (registration No. 333-265900) filed with the SEC on November 16, 2022. Forward-looking statements speak only as of the
date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn
that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and
links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference
into this press release. Clearmind is not responsible for the contents of third-party websites.